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BACKGROUND: Digalloyl-resveratrol (di-GA) is a synthetic compound aimed to combine the biological effects of the plant polyhydroxy
phenols gallic acid and resveratrol, which are both radical scavengers and cyclooxygenase inhibitors exhibiting anticancer activity.
Their broad spectrum of activities may probably be due to adjacent free hydroxyl groups.
METHODS: Protein activation and expression were analysed by western blotting, deoxyribonucleoside triphosphate levels by HPLC,
ribonucleotide reductase activity by
14C-cytidine incorporation into nascent DNA and cell-cycle distribution by FACS. Apoptosis was
measured by Hoechst 33258/propidium iodide double staining of nuclear chromatin and the formation of gaps into the
lymphendothelial barrier in a three-dimensional co-culture model consisting of MCF-7 tumour cell spheroids and human
lymphendothelial monolayers.
RESULTS: In HL-60 leukaemia cells, di-GA activated caspase 3 and dose-dependently induced apoptosis. It further inhibited cell-cycle
progression in the G1 phase by four different mechanisms: rapid downregulation of cyclin D1, induction of Chk2 with simultaneous
downregulation of Cdc25A, induction of the Cdk-inhibitor p21
Cip/Waf and inhibition of ribonucleotide reductase activity resulting in
reduced dCTP and dTTP levels. Furthermore, di-GA inhibited the generation of lymphendothelial gaps by cancer cell spheroid-
secreted lipoxygenase metabolites. Lymphendothelial gaps, adjacent to tumour bulks, can be considered as gates facilitating metastatic
spread.
CONCLUSION: These data show that di-GA exhibits three distinct anticancer activities: induction of apoptosis, cell-cycle arrest and
disruption of cancer cell-induced lymphendothelial disintegration.
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Digalloyl-resveratrol (di-GA) is a synthetic ester of the phytoalexin
resveratrol (3,40,5-trihydroxystilbene; RV) and the polyhydroxy
phenolic compound gallic acid (3,4,5-trihydroxybenzoic acid; GA)
(Figure 1). Gallic acid can be found in various natural products,
such as green tea, pineapples, bananas, apple peels, red and
white wine (Sun et al, 2002; De Beer et al, 2003; Wolfe et al,
2003). Resveratrol is a constituent of red wine and grapes. Both
compounds are proposed to contribute to the ‘French Paradox’,
a phenomenon of significantly lower (40%) heart infarction
incidence in the French population, when compared with other
European countries or the United States (Richard, 1987; Renaud
and De Lorgeril, 1992; Constant, 1997). Gallic acid and RV were
also described as excellent free radical scavengers (Inoue et al,
1994; Isuzugawa et al, 2001; Kawada et al, 2001; Salucci et al, 2002;
Sohi et al, 2003; Horvath et al, 2005) and as inducers of differen-
tiation and programmed cell death in a variety of tumour cell lines.
Other beneficial properties of GA-containing fruit extracts include
anti-diabetic and anti-angiogenic effects (Liu et al, 2005; Sridhar
et al, 2005). Gallic acid is also present at high concentrations in
gallnuts (name), which are proliferations of plant leaves that
become elicited by gall wasp exudates to build up a hatchery for
their larvae. Thus, the secretion of gall wasps stimulates plant cell
growth and overrules homeostasis of the affected leaf area – this is
similar to tumour outgrowth. In turn, the plant produces GA,
which seems to combat the improper growth signals and
re-establishes cell-cycle control. This could at least explain why
gallnuts are rich in GA and that gallnuts do not grow beyond a
certain size. This cytostatic property of GA – which is amplified in
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variety of fruits and this could also be developed for adjuvant
therapy.
Gallnuts are not used in modern western medicine, but they
were mentioned in the first book of ‘De Materia Medica’ ascribed
to Pedanios Dioscurides (the ‘Vienna Dioscurides’, Austrian
National Library, which was written in the sixth century in
Konstantinopolis, East Roman Empire). Interestingly, this manu-
script claims that gallnuts ‘stop the growth of proliferating tissue’.
Other studies showed that RV and GA are effective inhibitors of
the enzyme ribonucleotide reductase (RR; EC1.17.4.1) (Fontecave
et al, 1998; Madlener et al, 2007). Ribonucleotide reductase is
significantly upregulated in malignant cells compared to non-
malignant cells. This enzyme catalyses the rate-limiting step of
de novo DNA synthesis, which is the reduction of ribonucleotides
into the corresponding deoxyribonucleoside triphosphates
(dNTPs). This qualifies RR as an excellent target for cancer
chemotherapy.
Apart from being a radical scavenger, the multifactorial effects
of GA encompass also the inhibition of cyclooxygenases (COXs)
and of lipoxygenases (LOXs). Tumours express high levels of
COX-2 and 12-LOX (Nie et al, 2003; Pidgeon et al, 2003; Nassar
et al, 2007), which metabolise arachidonic acid to prostanoids and
to hydroxyeicosatetraenoic acids (12(S)-HETE), respectively
(Marks et al, 2000). Certain HETEs function as inter- and
intracellular messengers and cause the repulsion of endothelial
cells thereby forming gaps in the endothelial cell layer (Ohigashi
et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). Further, these
gaps may serve as entry ports for adjacent tumour cells into the
lymphatic system. Thus, we hypothesised that GA (and di-GA)
may inhibit lymphendothelial gap formation. Here we examine the
effects of di-GA on apoptosis, cell-cycle progression and lym-
phendothelial gap formation.
MATERIALS AND METHODS
Chemicals
Nordihydroguaiaretic acid (NDGA) was from Cayman Chemical
(Ann Arbor, MI, USA); and aspirin, mannitol, probucol, GA and
RV were from Sigma-Aldrich (Vienna, Austria). Catalase and
carboxy-PTIO were from Calbiochem-Merck Biosciences
(Nottingham, UK). Berberine chloride dihydrate (purity 98.92%)
was from Phytolab (Vestenbergsgreuth, Germany). Experimental
stock solutions (in DMSO) were prepared always fresh.
Mouse monoclonal anti-Cdc25A (F-6) Cat. No. 7389; anti-
PARP-1 (F-2) Cat. No. sc-8007; anti-cyclin D1 (M-20) Cat. No. sc-
718; anti-cyclin E (M20) Cat. No. sc-481 and anti-p21
Cip/Waf (C-19)
Cat. No. sc-397 antibodies were from Santa Cruz Biotechnology
Inc. (Heidelberg, Germany). Polyclonal anti-phospho-Cdc25A
(Ser17) Cat. No. ab18321 antibody was from Abcam (Cambridge,
UK); and monoclonal anti-p34
Cdc2 Cat. No. C3085 and anti-b-actin
(AC15) Cat. No. A5441 antibodies were from Sigma-Aldrich.
Rabbit monoclonal anti-cleaved caspase 3 (CPP32) clone C92-605
Cat. No. 58404 antibody was from Research Diagnostics Inc.
(Flanders, NJ, USA). Polyclonal anti-MEK 1/2 Cat. No. 9122; anti-
phospho-MEK 1/2 (Ser217/221) Cat. No. 9121 m; anti-phospho-
Chk2 (Thr68) Cat. No. 2661; anti-Chk2 Cat. No. 2662 and rabbit
monoclonal anti-p44/42 MAP Kinase (137F5) Cat. No. 4695;
anti-phospho-Cdc2 (Tyr15) Cat. No. 4539 and mouse monoclonal
anti-phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Cat. No.
9106 antibodies were from Cell Signaling Technology Inc.
(Danvers, MA, USA). Anti-mouse IgG was from Dako (Vienna,
Austria). Anti-rabbit IgG and Amersham ECL – high-performance
chemiluminescence film – were from GE Healthcare (Vienna,
Austria).
Cell culture
HL-60 human promyelocytic cells were purchased from ATCC
(Wesel, Germany). Cells were grown in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum, 1%
L-glutamine and 1% penicillin/streptomycin. MCF-7 cells were
grown in McCoy 5A medium containing 10% fetal calf serum
and 1% penicillin/streptomycin. Human normal lung fibro-
blasts (HLF) were a generous gift of the Cancer Research Institute
of the Medical University of Vienna and were grown in RPMI
medium containing 10% fetal calf serum and 1% penicillin/
streptomycin. All media, supplements and G418 were obtained
from Life Technologies (Lofer, Austria).
Human dermal microvascular endothelial cells (C-12260) were
purchased from PromoCell (Heidelberg, Germany). To obtain
a population of highly enriched lymphendothelial cells (LECs)
dermal microvascular endothelial cells were sorted with poly-
clonal rabbit anti-human podoplanin antibody and sheep anti-
rabbit dynabeads (M-280; Dynal 11203; Invitrogen, Lofer,
Austria). Subsequently, residual cells were sorted with anti-CD31
(Dynal 11128). Incubations were performed at 41C for 30min.
Such isolated LECs were stable transfected with telomerase
cDNA and then maintained in EGM2 Mv medium (EBM2-based
medium CC3156 and supplement CC4147; Lonza, Walkersville,
MD, USA) and G-418 (Schoppmann et al, 2004). All cell
types were kept in humidified atmosphere containing 5% CO2 at
371C.
Proliferation inhibition assay
HL-60 cells were seeded in T-25 tissue culture flasks at a
concentration of 1 10
5 per ml and incubated with increasing
concentrations of di-GA (2.5, 5, 7.5, 10 and 40mM). Cell numbers
and IpC50 values were determined after 24 and 48h using a CC-108
microcellcounter (Sysmex, Kobe, Japan).
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Figure 1 Chemical structures of (A) gallic acid (GA) and (B) digalloyl-
resveratrol (di-GA).
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The extraction of cellular dNTPs was performed according to a
method described previously (Garrett and Santi, 1979). HL-60 cells
(7 10
7) were incubated with 5, 10 and 40mM di-GA for 24h. Then,
1 10
8 were centrifuged at 1800r.p.m. and resuspended in 100ml
phosphate-buffered saline (PBS) and extracted with 10ml trichloro-
acetic acid. The lysate was rested on ice and neutralised by adding
1.5 vol of freon containing 500mM tri-n-octylamin. Afterwards the
lysate was centrifuged (15000r.p.m. for 4min) and the super-
natant was used for periodation (100ml extract þ30ml4 M
methylamine (pH 7.5)þ10ml periodat). Aliquots (120ml) of each
sample were analysed using a Merck ‘La Chrom’ HPLC-system
equipped with D-7000 interface, L-7100 pump, L-7200 autosampler
and L-7400 UV-detector. Detection time was set at 80min, the
detector operated on 280nm for 40min and then switched to
260nm for another 40min. Samples were eluted with a 3.2 M
ammonium phosphate buffer, pH 3.6 (pH adjusted by addition of
3.2 M H3PO4), containing 20moll
 1 acetonitrile using a
4.6 250mm Partisil 10 SAX column (Whatman Ltd., Kent, UK).
Separation was performed at constant ambient temperature and at
a flow rate of 2mlmin
 1. The concentrations of each dNTP of the
experimental samples were then calculated as percent of total area
under the control curves. Chemicals were from Sigma-Aldrich and
of highest available quality.
Hoechst 33258 and propidium iodide double staining
The vitality staining was performed according to a protocol
described before (Grusch et al, 2002). HL-60 cells (0.4 10
6 per
ml) were seeded in T-25 tissue culture flasks and exposed to
increasing concentrations of di-GA (2.5, 5, 7.5, 10 and 40mM)
for 24h. Hoechst 33258 and propidium iodide were purchased
from Sigma-Aldrich and added directly to the cells at final
concentrations of 5 and 2mg/ml, respectively. After 60min of
incubation at 371C, we examined cells with a Zeiss Axiovert
fluorescence microscope and a DAPI filter (Carl Zeiss, Jena,
Germany). Cells were photographed and analysed by visual
examination (not by FACS). This method allows to distinguish
between early apoptosis, late apoptosis and necrosis. Cells were
judged according to their nuclear morphology and the disinte-
gration of their cell membranes, which is indicated by propidium
iodide uptake.
Cell-cycle distribution analysis
HL-60 cells (0.4 10
6 per ml) were seeded in T-25 tissue culture
flasks and incubated with 2.5, 5, 10 and 40mM di-GA. After 24h,
cells were harvested, washed with 5ml cold PBS, centrifuged
(600r.p.m. for 5min) and resuspended and fixed in 3ml ethanol
(70%) at 41C for 30min. After two further washing steps with cold
PBS, RNAse A and propidium iodide were added to a final
concentration of 50mgml
 1 each and incubated at 41C for 60min
before analysis on a FACSCalibur flow cytometer (BD Biosciences,
San Jose, CA, USA). The cell-cycle distribution was calculated with
ModFit LT software (Verity Software House, Topsham, ME, USA).
Determination of RR in situ activity
Exponentially growing HL-60 cells (5 10
5) were incubated with 1,
2.5 and 5mM di-GA for 24h at 371C in a humidified atmosphere
containing 5% CO2 to assess changes in RR in situ activity. Then,
cells were pulsed with
14C-cytidine (Sigma-Aldrich; 3mli na5 m l
cell suspension) at 371C for 30min, collected by centrifugation
(1200r.p.m. for 5min), washed twice with PBS and processed to
extract total genomic DNA. Thereafter, the radioactivity, which
became incorporated into genomic DNA, was measured.
Western blotting
HL-60 cells (1.5 10
7 cells) were seeded into T-75 tissue culture
flasks and incubated with 10mM di-GA for 0.5, 2, 4, 8 and 24h.
Then, 1 10
6 cells were harvested (per experimental point),
washed twice with cold PBS, centrifuged at 1000r.p.m. for 5min
and lysed in a buffer containing 150mM NaCl, 50mM Tris (pH 8.0),
1% Triton X-100, 1mM phenylmethylsulfonyl fluoride and protease
inhibitor cocktail (from a  100 stock; Sigma-Aldrich). The lysates
were centrifuged at 41C for 20min (12000r.p.m.) and super-
natants stored at  20 1C until further analysis. Equal amounts of
protein samples were separated by polyacrylamide gel electro-
phoresis and electroblotted onto PVDF membranes (Hybond, GE
Healthcare) at 41C overnight. Equal sample loading was controlled
by staining membranes with Poinceau S (Sigma-Aldrich). After
washing with PBS/0.5% Tween 20 (PBS/T) (pH 7.2) or TBS/0.1%
Tween 20 (TBS/T) (pH 7.6), membranes were blocked for 1h in
blocking solution (5% non-fat dry milk in PBS/T or in TBS/T). The
membranes were incubated with the first antibody (in blocking
solution, dilution 1:500–1:1000) by gently rocking at 41C
overnight. Thereafter, the membranes were washed with PBS or
TBS and further incubated with the second antibody (peroxidase-
conjugated goat anti-rabbit IgG or anti-mouse IgG, dilution
1:2000–1:5000 in PBS/T or TBS/T) for 12h. Chemoluminescence
was developed by the ECL detection kit and the exposure of
membranes to Amersham Hyperfilms (GE Healthcare).
MCF-7 spheroid generation
1.2g of autoclaved methyl cellulose (M-0512; Sigma-Aldrich) was
resuspended in 100ml prewarmed McCoy 5A medium (Life
Technologies; 1.2% stock concentration), stirred until the solution
turned clear and centrifuged at 4000r.p.m. (swing out rotor) for
2h to pellet undesired debris. Then, 1 10
5 MCF-7 cells were
transferred to 15ml McCoy 5A medium containing 0.24% methyl
cellulose (final concentration). 150ml (containing B1 10
3 cells)
was transferred to each well of a round bottom microtitre plate
(96-well) to allow spheroid formation. Cells were allowed to
aggregate and grow for 2 days, and then spheroids were sufficiently
dense for further manipulations. MCF-7 spheroids had an average
diameter of B300mm.
MCF-7 spheroid/LEC monolayer co-cultivation
LECs were seeded in EGM2 MV medium on 24-well plates and
allowed to grow for 2–3 days until confluence. Then, LECs were
stained with cytotracker green (concentration 2mgml
 1 final
concentration, Molecular Probes-C2925, Invitrogen) at 371C for
90min and subsequently rinsed thoroughly. Thereafter, MCF-7
spheroids were washed in EGM2 MV medium to rid off methyl
cellulose, and 12 spheroids were carefully transferred using wide
bore yellow tips to each well containing LECs.
For those experiments in which inhibitors were used, the
indicated inhibitor concentrations (final concentrations) were
applied to the spheroids 30min prior addition of the spheroids
to the LEC layers.
Analysis of gap formation
LEC areas with spheroids on top were photographed using an FITC
filter, which was used to visualise cytotracker (green)-stained LECs
underneath the spheroids. Axiovert software (Carl Zeiss) facilitated
to measure the gap areas within the LEC layers.
Statistical calculations
Dose–response curves were calculated using the Prism 4.03
software package (GraphPad, San Diego, CA, USA) and statistical
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cance Po0.05).
RESULTS
Quite a few studies on GA and its derivatives, RV and RV
analogues were performed in human leukaemia cells (Saiko et al,
2008), because these cells are very sensitive to drugs and therefore
advantageous to test the efficacy of novel anticancer compounds.
HL-60 cells are particularly useful to discriminate the nuclear
morphology of necrotic and apoptotic cells (Grusch et al, 2002)
and hence, we used HL-60 cells to study di-GA facilitating the
comparability of our results with published data of other GA and
RV analogues.
Di-GA induces caspase 3 and apoptosis
The pro-apoptotic potential of naturally occurring GA was
compared to that of synthetic di-GA by incubating HL-60
promyelocytic leukaemia cells to both agents (Figure 2A and B).
Increasing concentrations of GA (10, 20, 40 and 80mM) elicited 4,
10, 34 and 60% apoptosis, respectively. Because the di-GA
molecule contains two galloyl residues (as compared to just one
gallic acid molecule of GA) we expected that half of the di-GA
concentrations would induce similar apoptosis rates as the tested
GA concentrations. However, 5, 10 and 40mM di-GA (to compare it
to 10, 20 and 80mM GA, see above) triggered 12, 39 and 84%
apoptosis, respectively. In an earlier study, we showed that 25 and
50mM RV induced B18 and 45% apoptosis in HL-60 cells,
respectively (Horvath et al, 2006). Therefore, the apoptotic
efficiency of di-GA is the sum of the apoptotic properties of
2  GA plus RV. Apoptosis correlated with the activation of
caspase 3 and with the signature type cleavage of PARP into
an 85kDa fragment (Figure 2C). Digalloyl-resveratrol did not
induce significant numbers of necrotic cells even at high
concentrations (data not shown). The data suggest that di-GA is
a potent inducer of apoptosis and significantly more effective than
GA alone.
Di-GA inhibits G1-S transition
HL-60 cells were exposed to increasing concentrations of GA and
di-GA and the cell numbers were measured after 24 and 48h. The
percentages of proliferation inhibition were calculated at both time
points. Those concentrations that inhibited 50% proliferation
(IpC50) are shown in Table 1. Digalloyl-resveratrol inhibited
proliferation 7–10 times more efficiently than GA during the
tested time period. Inhibition of cell proliferation was due to a
dose-dependent cell-cycle block in G1 (Figure 3A).
Di-GA modulates mitogenic signalling and the expression
of cell-cycle regulators
We next examined the levels of the cell-cycle inhibitor p21
Cip/Waf,
which is known to inhibit Cdk2 by blocking its interaction with
cyclin E (Jeon et al, 2007). p21
Cip/Waf was induced within 4h
(Figure 3B), which was independent of p53, because HL-60 cells
are p53 negative (Biroccio et al, 1999). Phosphorylation of Erk1
and MEK, which is indicative for their activation, preceded the
increase in p21
Cip/Waf levels. This is consistent with previous
reports that MEK-Erk signalling upregulates p21
Cip/Waf
(Facchinetti et al, 2004; Park et al, 2004; Perez-Pinera et al,
2006). Phosphorylation of Erk2 (the lower band occurring after 4
and 8h) was simultaneous to p21
Cip/Waf upregulation. Next, we
investigated whether the expression of the G1-specific cell-cycle
regulators Cdc25A, cyclin D1 and cyclin E was altered by di-GA
treatment (10mM). Western blot analyses showed that cyclin D1
expression decreased after 2h and remained suppressed, whereas
cyclin E expression persisted (Figure 3C). Cyclin D1 is required for
the activation of Cdk4 and Cdk6 (Lingfei et al, 1998; Alao, 2007),
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Figure 2 Induction of apoptosis by (A) GA and (B) di-GA in HL-60
cells. Cells were incubated with increasing concentrations of drugs for 24h,
and then double stained with Hoechst 33258 and propidium iodide.
Afterwards cells were examined under the microscope with UV light
connected to a DAPI filter. Nuclei with a morphological phenotype
indicating apoptosis were counted and percentages of apoptotic cells were
calculated. Experiments were conducted in triplicate. Error bars indicate
s.e.m., asterisks significance (Po0.05). (C) Activation of caspase 3 and
cleavage of PARP on treatment with di-GA. Logarithmically growing HL-60
cells were incubated with 10mM di-GA for 0.5, 2, 4, 8 and 24h. Afterwards
cells were lysed and protein expression was analysed by western blotting.
The anti-caspase 3 antibody recognises only the cleaved peptide indicating
its activation. Anti-PARP antibody recognises the full-length form (116kDa)
and the signature-type cleaved product (85kDa) that is generated by active
caspase 3. The antibody against b-actin was used to monitor equal sample
loading.
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swhich altogether is controlled by Cdc25A (Iavarone and Massague,
1997). Digalloyl-resveratrol strongly induced serine 17 (Ser17)
phosphorylation of Cdc25A after 4h. Phosphorylation of Ser17-
Cdc25A was shown to stabilise this phosphatase at a high activity
status specifically in the M phase (Mailand et al, 2002), thereby
de-phosphorylating and activating its target Cdk1 (Cdc2). This is
mandatory for the transit through the G2-M phase (Karlsson-
Rosenthal and Millar, 2006). Hence, Cdc25A controls not only the
G1-S, but also the G2-M phase. Indeed, di-GA caused the
de-phosphorylation of Tyr15-Cdc2 indicating that cells entered
the mitotic phase. FACS analysis confirmed that 40mM di-GA
allowed B90% of the cells to pass through S and M phase (likely
due to Cdc25A activity) but accumulated in the subsequent G1
phase because cyclin D1 was repressed. Finally, Cdc25A protein
level decreased after 24h. This was paralleled by Chk2 activation
(indicated by its phosphorylation at Thr68), presumably due to
replicatory stress. Chk2 targets Cdc25A for proteolytic degra-
dation (Karlsson-Rosenthal and Millar, 2006). In summary, the
data suggest that di-GA inhibits cell proliferation by disturbing
orchestrated mitogenic signalling.
Di-GA inhibits RR
Gallic acid is a radical scavenger (Whang et al, 2005) and inhibits
RR through chelating the tyrosyl radical required for RR activity
(Madlener et al, 2007). Ribonucleotide reductase is the rate-
limiting enzyme for nucleotide metabolism necessary for DNA
synthesis during cell division.
Hence, RR activity was investigated by an assay that measures
the incorporation of
14C-cytidin into genomic DNA. Figure 4A
shows that
14C-cytidin incorporation into genomic DNA decreased
with increasing di-GA concentration. Further, RR activity was fully
blocked on treatment with 5mM di-GA. At this concentration the
dCTP level (but not dTTP and dATP) dropped significantly
(Figure 4B). In HT29 colon carcinoma cells, a similar effect of
di-GA on RR activity, dCTP, dTTP and dATP levels was observed
(Bernhaus et al, 2009).
Table 1 Concentrations of GA and di-GA that inhibit proliferation of
HL-60 cells by 50%
IpC50 (24h) (lM)I pC50 (48h) (lM)
GA 21 24
Di-GA 4 2
Cell cycle distribution of
di-GA-trated HL-60 cells
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Figure 3 Effect of di-GA on the cell cycle of HL-60 cells. (A) Logarithmically growing HL-60 cells were incubated with increasing concentrations of di-GA
for 24h and then subjected to FACS analysis. Experiments were conducted in triplicate. Error bars indicate s.e.m., asterisks significance (Po0.05). HL-60 cells
were incubated with 10mM di-GA for 0.5, 2, 4, 8 and 24h, lysed, and the (B) expression of p21
Cip/Waf, the phosphorylation of threonine202/tyrosine204-
Erk1/2 (p-Erk1/2) and serine217/221-MEK1/2 (p-MEK), and (C) phosphorylation of threonine68-Chk2 (p-Chk2), serine17-Cdc25A (p-Cdc25A), tyrosine15-
Cdc2 (p-Cdc2), and the protein levels of cyclin D1, E were analysed by western blotting. b-Actin served as loading control.
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by co-cultivated tumour cell spheroids
Leukocytes trespass basal membranes and trans-migrate tissues
and endothelia as part of their normal physiological function and
are therefore, a priori ‘invasive’. Hence, HL-60 leukaemia cells
are inappropriate to study the pathological invasiveness of cancer
cells and the anti-invasive/anti-metastatic potential of di-GA.
In contrast, solid tumours acquire an invasive potential in course
of cancer progression and this particular cancer cell property has
to be studied and combated. We developed a novel bulk invasion
assay to establish an in vitro model resembling the pathologic
situation of ductal breast cancer cells invading the lymphatic
vasculature and to recapitulate the mechanism of metastasis
(Ohigashi et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). For
this, telomerase immortalised human LECs were grown to
confluent monolayers and MCF-7 tumour spheroids (average
diameter B300mm, containing B4000 cells) were placed on top to
mimic tumour intrusion into lymphatics. Lymphendothelial cells
were pre-labelled with cyto-tracker (green) immediately before
co-cultivation, to monitor presence or absence of LECs underneath
tumour spheroids (Figure 5A). Normal HLF spheroids served as
negative controls, because these primary cells with limited lifespan
(Hayflick limit) are non-malignant and do not invade blood or
lymphatic vasculature. After 4h of co-cultivation, gaps formed
underneath 499% of the MCF-7 tumour spheroids (gap area was
on average B1.15 10
5mm
2) whereas no or only small gaps were
formed underneath normal lung fibroblasts. The gap size area was
measured underneath at least 12 spheroids and in triplicate
experiments. These gaps resemble entry ports for cancer cell bulks
invading the lymphatic system, which is now widely accepted to be
a route for the spreading of certain cancers (Alitalo et al, 2005;
Oliver and Alitalo, 2005; Sipos et al, 2005).
Di-GA inhibited gap formation dose-dependently and maxi-
mally by 460% (Figure 5B). We have evidence (time-laps movies;
data not shown) that gap formation is caused by LEC migration.
Berberine was reported to inhibit cell migration and invasion of
SCC-4 tongue squamous cancer cells (Ho et al, 2009) and HONE1
nasopharyngeal cancer cells (Tsang et al, 2009). The chemical
structure of berberine is reminiscent to parts of di-GA and for
control reasons we tested whether berberine had an effect on MCF-
7-induced LEC behaviour. Berberine dose-dependently inhibited
gap formation and this confirmed that the assay was functional
and responded according to prediction.
Primary cancers and also MCF-7 breast cancer cells express
elevated levels of LOXs, which metabolise arachidonic acid to
HETEs (Marks et al, 2000; Nie et al, 2003; Kudryavtsev et al, 2005).
The migration of endothelial cells was shown to be mediated by
LOXs generating 12(S)-HETE (Ohigashi et al, 1989; Nakamori et al,
1997; Uchide et al, 2007). 12(S)-HETE functions as inter- and
intracellular messenger and causes the retraction of endothelial
cells, thereby forming gaps into the confluent cell layer. The 12/
15-LOX inhibitors baicalein (100mM) and NDGA (50mM) reduced
the area of MCF-7 spheroid-induced gaps in the LEC monolayers
by B50 and 60%, respectively. Derivatives of GA are also known to
inhibit HETE generating LOXs, and prostanoids generating COXs
(Christow et al,1 9 9 1 ;H aet al, 2004; Kim et al,2 0 0 6 ) .H o w e v e r ,
because aspirin had no effect on gap formation (Figure 5B) the
contribution of COXs can be excluded. We also took into account
that NDGA, baicalein, GA and di-GA are powerful radical scavengers
and antioxidants (Sohi et al, 2003; Floriano-Sanchez et al,2 0 0 6 ) .I n
case LEC gaps were induced by radicals, gap formation should be
inhibited by radical scavengers. To test this possibility, we analysed
the efficacy of four bona fide ROS scavengers. In particular, we used
mannitol, which scavenges the OH
K radical; probucol, which is an
effective inhibitor of lipid peroxidation; catalase, which is an H2O2
catabolising enzyme; and carboxy-PTIO, which scavenges the NO
K
radical. These scavengers did not prevent LEC gap formation.
Therefore, MCF-7-induced gap formation was independent of a
potential radical involvement.
Finally, we tested whether isolated GA and RV inhibited LEC gap
formation. Whereas 50mM RV inhibited gap size by B25%, 80mM
GA was ineffective. Therefore, GA did not affect cell migration,
which was in contrast to a galloyl glucose derivate that inhibited
tube formation of human microvessel endothelial cells (Lee et al,
2004). Methyl gallate influences 5-LOX (Kim et al, 2006) and GA
may also inhibit this enzyme. However, 5-LOX did not contribute
to LEC gap formation, because 100mM caffeic acid did not reduce
gap size (data not shown). This indicated that RV, but not GA, was
the inhibitory principle being improved by the higher complex
structure of di-GA.
In summary, di-GA dose-dependently inhibited LEC gap
formation with an efficiency similar to that of NDGA. The strong
anti-invasive property of di-GA is apparently due to the novel
chemical structure of the compound, but not due to the GA
residues, and only in part due to RV.
DISCUSSION
Gallic acid is a polyhydroxylated phenol previously known to
scavenge radicals, inhibit RR, COXs, LOXs, arrest cell cycle and
induce apoptosis (Ha et al, 2004; Faried et al, 2007; Hsu et al, 2007;
Madlener et al, 2007).
Here we tested a novel synthetic GA derivate, di-GA, assuming
that this compound may exhibit superior activity than GA itself.
In situ measurement of
RR activity
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Figure 4 (A) Measurement of the in situ effect of di-GA on
ribonucleotide reductase (RR) activity. HL-60 cells were incubated with
1, 2.5 and 5mM di-GA for 24h at 371C in a humidified atmosphere
containing 5% CO2 to assess changes in RR in situ activity. Then, cells were
pulsed with
14C-cytidine (Sigma-Aldrich; 3ml in a 5ml cell suspension) for
30min at 371C. Afterwards the cells were collected and the radioactivity
that became incorporated into genomic DNA was measured. (B) Effect of
di-GA on intracellular dNTP pools in HL-60 cells. HL-60 cells were
incubated with 5, 10 and 40mM di-GA for 24h. Then the cells were
prepared for HPLC analysis and the dNTP levels were determined
according to the protocol described in the ‘Materials and methods’ section.
Experiments were conducted in triplicate. Error bars indicate s.e.m.,
asterisks significance (Po0.05).
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sIn fact, the pro-apoptotic property of 10mM di-GA exceeded that
of 20mM GA by four-fold. Thus, an additional pro-apoptotic
mechanism, apart from two galloyl residues, contributed to cell
death especially at low concentrations. This is of particular interest
because such concentrations can be achieved in humans. The
RV backbone, to which the galloyl residues are connected, may
be responsible for the additive effect, because RV was previously
reported to induce apoptosis in HL-60 cells (Horvath et al,
2006). The apoptotic activity of di-GA was much higher than the
reported RV activity (50mM RV induced 50% apoptosis in HL-60),
but the apoptotic activity of the RV derivative, 3,30,4,40,5,
50-hexahydroxystilbene (M8) was even higher than that of di-GA
(Horvath et al, 2006). In contrast, another RV derivative with
anti-neoplastic properties, N-hydroxy-N0-(3,4,5-trimethoxyphenyl)-
3,4,5-trimethoxy-benzamidine (KITC), induced HL-60 apoptosis
less efficiently (Saiko et al, 2007). Digalloyl-resveratrol triggered
apoptosis through the caspase 3 pathway yet independent of
p53, because HL-60 cells are p53 deficient (Biroccio et al, 1999).
Because more than 50% of all cancer types harbour a defective p53
pathway, which is detrimental to successful therapeutic treatment,
compounds that exert anticancer activity independent of p53 are
of particular interest for clinical applications.
Another prominent anticancer property of therapeutic drugs is
to arrest the cell cycle. This can be achieved by blocking distinct
mechanisms such as cell-cycle regulators or enzymes involved in
DNA-replicative processes etc. Here we show that di-GA inhibited
3D Spheroids and LEC co-cultivation (4 h)
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Figure 5 Effect of di-GA on MCF-7 spheroid-induced gap formation in lymphendothelial cell monolayers. (A) LEC monolayers that were exposed to
MCF-7 spheroid (left side panels), MCF-7 spheroid treated with 40mM di-GA (middle panels) and HLF spheroid (right side panels). Upper panels are phase-
contrast micrographs showing the respective spheroids, the panels below show the identical power fields using FITC filter and exhibit green stained LECs
underneath the respective spheroids. Bars in the lower right corners of upper panels indicate 100mM.( B) MCF-7 tumor spheroids were preincubated with
solvent (control), or 5 and 50mM berberine; 5, 10, 25, 40 and 80mM di-GA; 80mM GA; 50mM RV; 50mM NDGA; 100mM baicalein; 200mM aspirin; 25mM
mannitol; 600Uml
 1 catalase; 200mM carboxy-PTIO and 100mM probucol, and then placed on top of cytotracker stained LEC monolayers that were also
treated with respective agents for 4h. Then, the size of the gaps that were formed in the LEC monolayers by MCF-7 spheroids (through repulsion of LECs)
was measured using an inverted microscope connected to an FITC filter and equipped with Axiovision 4.5 software (Carl Zeiss). As negative controls normal
human lung fibroblast (HLF) spheroids were used. Rho/rac (small GTPases regulating cell migration), LOX (lipoxygenase), COX (cyclooxygenases) and ROS
(reactive oxygen species) indicate which mechanisms and phenomena are inhibited by the respective agents. Experiments were conducted in triplicate, and
the underneath areas of at least 12 spheroids were analysed. Error bars indicate s.e.m., asterisks significance (Po0.05).
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scell proliferation 10-fold more efficiently than GA (Madlener et al,
2007). This again suggests that the RV backbone synergised with
the two galloyl residues. Similar to GA, di-GA also inhibited HL-60
cell cycle in G1 (Madlener et al, 2007). Resveratrol and its analogue
M8 were shown to inhibit the cell cycle in S phase (Ragione et al,
1998; Horvath et al, 2006) and, therefore, the G1-inhibitory effect
of the GA moieties was dominant over that of the RV backbone in
the di-GA molecule. Interestingly, also KITC inhibited the HL-60
cell cycle in G1 phase (Saiko et al, 2007). Digalloyl-resveratrol
caused cell-cycle arrest by four independent mechanisms:
(i) Di-GA downregulated cyclin D1 and thus presumably
inhibited Cdk4 and/or Cdk6. Cyclin D1 was identified as
the Prad 1 oncogene, which is overexpressed in many types of
cancer (Lingfei et al, 1998; Alao, 2007). Therefore, suppres-
sion of cyclin D1 is a relevant target to combat cancer.
(ii) Di-GA induced p21
Cip/Waf and, therefore, affected Cdk2. Both
Cdk2- and Cdk4-activity are mandatory for G1-S transit. Hence,
blocking Cdk4 and Cdk2 inhibits cell division. p21
Cip/Waf
upregulation was independent of p53, because HL-60 cells
are p53 deficient. Consistent with reports that p21
Cip/Waf is also
induced by the MEK–Erk pathway (Facchinetti et al,2 0 0 4 ;P a r k
et al, 2004), we found that di-GA triggered Erk1(p44Thr202)-
phosphorylation within 30min and MEK1(Ser217)-phosphory-
lation within 2h. Further, Erk2(p42Tyr204)-phosphorylation
occurred at 4h, which was simultaneous with p21
Cip/Waf-
induction.
(iii) Di-GA stabilised Cdc25A by Ser17 phosphorylation and
forced cells through S and M phase. In consequence, B90%
of the cells accumulated in the following G1 phase due to
cyclin D1 suppression and p21
Cip/Waf induction. This may
have resulted in replicative stress because after 24h of di-GA
treatment Chk2 became activated, which was paralleled by
Cdc25A protein degradation. A similar effect was observed
on heat shock treatment, which also induces the ATM–Chk2
pathway resulting in the degradation of Cdc25A (Madlener
et al, 2009). In contrast, Agarwal et al (2006) observed an
almost immediate Cdc25ASer17 phosphorylation and Chk2
activation on treatment of DU145 cells with GA that was not
accompanied by degradation of Cdc25A.
(iv) Similar to GA, di-GA inhibited RR most probably by
chelating the tyrosyl radical that is required for RR activity
(Madlener et al, 2007). Resveratrol inhibits RR through a
similar mechanism (Fontecave et al, 1998). At 5mM di-GA
inhibited 50% of dCTP synthesis, whereas it was reported
that 50mM GA did not inhibit dCTP synthesis whatsoever
(Madlener et al, 2007). Digalloyl-resveratrol inhibited dCTP
synthesis also several-fold more efficiently than RV (Horvath
et al, 2005). This indicated that the galloyl residues
synergised with the RV backbone to inhibit DNA replication.
It has been shown that MCF-7 cells induce gap formation into
arterial endothelial cell layers by virtue of 12(S)-HETE secretion,
which is generated by LOXs metabolising arachidonic acid
(Kudryavtsev et al, 2005; Uchide et al, 2007). Gap formation was
due to LEC migration (retraction) but not due to apoptosis of
LECs, which was evidenced by microscopic time-laps movies (not
shown) and by berberine-mediated inhibition of migration (Ho
et al, 2009; Tsang et al, 2009). We extended this cell system using a
three-dimensional co-culture model consisting of MCF-7 spher-
oids and telomerase-immortalised primary human LECs (Schopp-
mann et al, 2004), because this closely resembles ductal breast
cancer bulks intruding the lymphatic vasculature. We showed that
MCF-7-triggered lymphendothelial gap formation could be re-
duced to 40% by NDGA, which is a potent inhibitor of 12/15-LOXs
but also a radical scavenger. Several gallate derivates are known to
inhibit LOXs (Christow et al, 1991; Ha et al, 2004; Kim et al, 2006),
to scavenge radicals (Whang et al, 2005) and to inhibit COX
(Madlener et al, 2007; Kim et al, 2006). However, neither radicals
nor COXs contributed to gap formation. Hence, baicalein- and
NDGA-mediated inhibition supports the notion that at least 50–
60% of gap formation was due to 12(S)-HETE generating LOX
activity. The property of di-GA that reduced LEC migration was
similar to that of NDGA. Also the tube formation of human
microvessel endothelial cells, which was inhibited by a galloyl
glucose derivate, was most likely due to the inhibition of cell
migration (Lee et al, 2004). Because 12/15-LOX contributes to
angiogenesis (Nie et al, 2000, 2006; Rose and Connolly, 2000) and
tumour metastasis (Liu et al, 1996; Jankun et al, 2006), di-GA may
prevent neo-vascularisation of tumours as well as infiltration of
cancer cells into the lymphatic vasculature. Another derivate,
galloyl glucose, blocked HT-1080 tumour invasion through gelatin
by inhibiting matrix metalloprotease-2 (MMP-2) and MMP-9 (Ata
et al, 1996). In our system, specific inhibition of MMP-2 and MMP-
9 with cell permeable small molecules exhibited only a weak effect
on MCF-7-mediated gap formation into LEC layers (data not
shown). Interestingly, 80mM GA did not decrease lymphendothelial
gap formation whereas 50mM RV inhibited gap formation by 25%
evidencing that the principal inhibitory activity was contributed by
RV and that the superior activity of di-GA was not the sum of RV
plus GA, but a new property of its own.
This is analogous to the observation that the RV derivate M8
exhibits not only improved but even new anti-neoplastic properties.
In particular, M8 inhibits ROCK1 expression in contrast to RV,
which even induces ROCK1 protein levels (Paulitschke et al, 2009).
ROCK1 supports migration, invasivity and lymph node metastasis
of melanoma cells. M8 inhibits melanoma lymph node metastasis in
an scid mouse model by B50% at a concentration that is compa-
rable to 50mM used in vitro (Paulitschke et al, 2009). Interestingly,
LEC gaps induced by melanoma spheroids could not be inhibited
by NDGA or baicalein suggesting that different cancer types invade
the lymphatic vasculature by a mechanism different of LOX. In
addition to the effects described above, RV and M8 are shown to
inhibit NF-kB (Holmes-McNary and Baldwin, 2000; Horvath et al,
2006). In preliminary investigations we found that specific
inhibition of NF-kB by small molecules significantly attenuated
LEC gap formation (data not shown). Whether di-GA affects
ROCK1 expression and/or NF-kB translocation remains to be
established. DMU-212 (3,4,5,40-tetramethoxystilbene) is another RV
derivate that exerts strong anti-neoplastic effects in breast
carcinoma cells by tubulin polymerisation, which is a mechanism
not induced by RV (Ma et al, 2008). Other approaches focus on RV
analogues with improved cellular uptake properties such as a
triacetate form of RV or vineatrol that both retain the anti-
neoplastic properties of RV (Colin et al, 2009).
In conclusion, we describe three distinct anticancer effects of
di-GA: the induction of apoptosis, the inhibition of cell division and
the inhibition of gap formation into lymphendothelial layers. Further,
we provide mechanistic explanations for the effect of di-GA on
apoptosis and cell cycle. For gap formation, we show the affection of
cell motility; however, an exact mechanism awaits elucidation.
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